Financials
By Ikaba Koyi
Date: Tuesday 21 Nov 2017
LONDON (ShareCast) - (ShareCast News) - NetScientific, the transatlantic healthcare IP commercialisation group, has today announced that ProAxsis, its portfolio company in which it holds a 57% stake, is forecasting higher direct sales of its ProteaseTag Active Neutrophil Elastase Immunoassay.
ProAxsis said it expected its NEIA sales to increase three-fold in the second half of 2017 versus the first six months of the year with total revenue expected to surpass £1m in 2018.
Commenting on the news, Francois Martelet, chief executive officer of NetScientific and Chairman of ProAxsis, said: "We are pleased to see signs of rapid market adoption of the CE marked NEIA test which uses ProAxsis' market leading ProteaseTag® technology. We are especially encouraged to see the acceleration of sales through a combination of repeat orders and new customers from leading research institutions across Europe and the US. We expect 2018 to be a pivotal year for ProAxsis with further planned product launches and potential industry partnerships as value inflection points."
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 70.00p |
Change Today | 2.00p |
% Change | 2.94 % |
52 Week High | 72.00 |
52 Week Low | 49.00 |
Volume | 106,367 |
Shares Issued | 23.95m |
Market Cap | £16.76m |
RiskGrade | 410 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
14:28 | 10,219 @ 69.08p |
14:52 | 4,000 @ 68.42p |
12:59 | 10,384 @ 68.65p |
13:40 | 7,418 @ 68.51p |
13:40 | 7,363 @ 68.51p |
CEO | Ilian Iliev |
CFO | Stephen Crowe |
You are here: research